Detailed Information on Publication Record
2019
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
HAJEK, Roman, Michel DELFORGE, Marc S. RAAB, Paul SCHOEN, Lucy DECOSTA et. al.Basic information
Original name
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Authors
HAJEK, Roman (203 Czech Republic, guarantor), Michel DELFORGE (56 Belgium), Marc S. RAAB (276 Germany), Paul SCHOEN (756 Switzerland), Lucy DECOSTA (826 United Kingdom of Great Britain and Northern Ireland), Ivan SPICKA (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), Sebastian GONZALEZ-MCQUIRE (756 Switzerland) and Walter BOUWMEESTER (528 Netherlands)
Edition
British journal of haematology, Hoboken, Wiley-Blackwell, 2019, 0007-1048
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.518
RIV identification code
RIV/00216224:14110/19:00112957
Organization unit
Faculty of Medicine
UT WoS
000480188400001
Keywords in English
algorithm; multiple myeloma; overall survival; relapsed; risk stratification
Změněno: 17/2/2020 10:09, Mgr. Tereza Miškechová
Abstract
V originále
Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61 center dot 6, 29 center dot 6, 14 center dot 2 and 5 center dot 9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations.